Stealth BioTherapeutics to Present at JMP Citizens Life Sciences Conference Press Release / May 6, 2024June 3, 2024
Stealth BioTherapeutics Completes Target Enrollment in Global Phase 3 NuPOWER Trial in Patients with Primary Mitochondrial Myopathy Press Release / September 11, 2023June 3, 2024
Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) Press Release / November 1, 2022June 3, 2024
Stealth BioTherapeutics to Participate in Upcoming Ultra-Rare Disease Events Press Release / September 15, 2022June 3, 2024
Stealth BioTherapeutics Presents New SBT-272 Data Demonstrating Improvement in Upper Motor Neuron Function in ALS Disease Model at Keystone Neurodegeneration Symposium Uncategorized / June 8, 2022June 3, 2024
Stealth BioTherapeutics Announces New SBT-272 Data and Trial Initiation Press Release / March 30, 2022June 3, 2024
